Method for treating congestive heart failure and other disorders
View Patent ↗Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
1. A method for treating a disorder selected from the groups consisting of congestive heart failure, hypertension, salt dependent high blood pressure, hepatic edema and liver cirrhosis, the method comprising administering to a subject in need thereof a composition comprising a polypeptide comprising the amino acid sequence: Xaa 1 Xaa 2 Xaa 3 Cys 4 Xaa 5 Xaa 6 Xaa 7 Xaa 8 Xaa 9 Xaa 10 Xaa 11 Cys 12 Xaa 13 Xaa 14 Xaa 15 Xaa 16 (SEQ ID NO:1) or a pharmaceutically acceptable salt thereof, wherein:
Xaa 1 is Ser, Asn, Tyr, Ala, Gln, Pro, Lys, Gly, or Thr, or is missing;
Xaa 2 is His, Asp, Glu, Ala, Ser, Asn, Gly, or is missing;
Xaa 3 is Thr, Asp, Ser, Glu, Pro, Val or Leu;
Xaa 5 is Asp, Ile or Glu;
Xaa 6 is Ile, Trp or Leu;
Xaa 7 is Cys, Ser, or Tyr;
Xaa 8 is Ala, Val, Thr, Ile, Met or is missing;
Xaa 9 is Phe, Tyr, Asn or Trp;
Xaa 10 is Ala, Val, Met, Thr or Ile;
Xaa 11 is Ala or Val;
Xaa 13 is Ala or Thr;
Xaa 14 is Gly, Ala or Ser;
Xaa 15 is Cys, Tyr or is missing; and
Xaa 16 is His, Leu or Ser.
2. The method of claim 1 wherein the polypeptide comprises the amino acid sequence Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO:44) or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 wherein the composition comprises a pharmaceutically acceptable carrier and the polypeptide comprising SEQ ID NO:1 or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 wherein the disorder is congestive heart failure.
5. A method for treating congestive heart failure comprising administering to a subject in need thereof a composition comprising a polypeptide comprising the amino acid sequence Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO:44) or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 wherein the polypeptide consists of the aminio acid sequence of SEQ ID NO: 1 or a pharmaceutically acceptable acceptable salt thereof.
7. The method of claim 2 wherein the polypeptide consists of the amino acid sequence Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO:44) or a pharmaceutically acceptable salt thereof.
8. The method of claim 3 wherein the composition comprises a pharmaceutically acceptable carrier and a polypeptide consisting of the amino acid sequence of SEQ ID NO:1 or a pharmaceutically acceptable salt thereof.
9. The method of claim 6 wherein the disorder is congestive heart failure.
10. The method of claim 5 wherein the polypeptide consists of the amino acid sequence Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO:44) or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 wherein the polypeptide comprises the amino acid sequence Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO:73) or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 wherein the polypeptide consists of the amino acid sequence Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO:73) or a pharmaceutically acceptable salt thereof.
13. A method for treating congestive heart failure comprising administering to a subject in need thereof a composition comprising a polypeptide comprising the amino acid sequence Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO:73) or a pharmaceutically acceptable salt thereof.
14. The method of claim 13 wherein the polypeptide consists of the amino acid sequence Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu (SEQ ID NO:73) or a pharmaceutically acceptable salt thereof.